UK firm to trial T-cell Covid vaccine that could give longer immunity
by Julia Kollewe from Science | The Guardian on (#5RXH1)
Exclusive: Oxfordshire-based Emergex gets go-ahead for trials in Switzerland for skin patch vaccine
An Oxfordshire-based company will soon start clinical trials of a second-generation vaccine against Covid-19, an easy-to-administer skin patch that uses T-cells to kill infected cells and could offer longer-lasting immunity than current vaccines.
Emergex was set up in Abingdon in 2016 to develop T-cell vaccines, the brainchild of Prof Thomas Rademacher, the firm's chief executive and professor emeritus of molecular medicine at the University College London medical school.
Continue reading...